Activators and inhibitors of NRF2: a review of their potential for clinical development
N Robledinos-Antón… - Oxidative medicine …, 2019 - Wiley Online Library
The transcription factor NRF2 (nuclear factor erythroid 2‐related factor 2) triggers the first
line of homeostatic responses against a plethora of environmental or endogenous …
line of homeostatic responses against a plethora of environmental or endogenous …
Treatment of multiple sclerosis—success from bench to bedside
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Background Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively
binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the …
binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the …
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Background Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to
receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that …
receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that …
Epidemiology and treatment of multiple sclerosis in elderly populations
CB Vaughn, D Jakimovski, KS Kavak… - Nature Reviews …, 2019 - nature.com
The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …
owing to increased longevity of the general population and the availability of effective …
[HTML][HTML] Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
X Montalban, DL Arnold, MS Weber… - … England Journal of …, 2019 - Mass Medical Soc
Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid
cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective …
cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective …
The immunomodulatory potential of the metabolite itaconate
A Hooftman, LAJ O'Neill - Trends in immunology, 2019 - cell.com
The field of immunometabolism has demonstrated that metabolites can lead double lives as
immunomodulators. Itaconate is perhaps the best example of such a moonlighting molecule …
immunomodulators. Itaconate is perhaps the best example of such a moonlighting molecule …
A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
Oxidative stress pathways in pancreatic β-cells and insulin-sensitive cells and tissues: importance to cell metabolism, function, and dysfunction
P Newsholme, KN Keane… - American Journal of …, 2019 - journals.physiology.org
It is now accepted that nutrient abundance in the blood, especially glucose, leads to the
generation of reactive oxygen species (ROS), ultimately leading to increased oxidative …
generation of reactive oxygen species (ROS), ultimately leading to increased oxidative …
Immunological aspects of approved MS therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …
to disability in young adults. The outcome of the disease is unpredictable, and over time …